IRulya Therapeutics (IRLA) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
REGENXBIO is the larger company by market cap ($473.4 million vs $432.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRLA | RGNX |
|---|---|---|
| Share price | $39.88 | $7.16 |
| Market cap | $432.36M | $473.44M |
| 1-day change | -0.15% | -0.28% |
| YTD return | — | -50.28% |
| 1-year return | — | -39.32% |
| 5-year return | — | -76.87% |
| EPS (TTM) | $-162.79 | $-3.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $170.44M |
| Revenue growth (YoY) | — | +104.54% |
| Net income (latest FY) | $-83.98M | $-193.88M |
| Operating margin | — | -94.58% |
| Net margin | — | -113.75% |
| 52-week high | $910.00 | $16.19 |
| 52-week low | $15.10 | $5.46 |
| Distance from 52-week high | -95.62% | -55.78% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +90.90% | +198.88% |
| Average volume | 63.03K | 1.39M |
| Shares outstanding | 10.84M | 66.12M |
| Employees | 38 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About IRulya Therapeutics
IRLA stock →IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
IRLA vs RGNX FAQ
Which is bigger, IRulya Therapeutics or REGENXBIO?
REGENXBIO (RGNX) is larger, with a market capitalization of $473.44M compared with $432.36M for IRulya Therapeutics (IRLA).
Are IRulya Therapeutics and REGENXBIO in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.